Insider Trading for Summit Therapeutics Inc.
SEC Form 4 insider transactions for Summit Therapeutics Inc. (SMMT)— latest filing: 2026-06-04
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Cluster Buy Detected
3 different insiders have purchased Summit Therapeutics Inc. stock in the last 30 days (excluding pre-planned 10b5-1 trades).
Overview
Recent Transactions (11)
| Insider | Date | Type | Value |
|---|---|---|---|
| DUGGAN ROBERT W | 2026-06-04 | Buy | $1.5M |
| Soni Manmeet Singh | 2026-06-04 | Buy | $361K |
| Soni Manmeet Singh | 2026-06-04 | Buy | $362K |
| Zanganeh Mahkam | 2026-06-04 | Buy | $1.5M |
| DUGGAN ROBERT W | 2025-10-21 | Buy | $500K |
| Zanganeh Mahkam | 2025-10-21 | Buy | $500K |
| Xia Yu | 2025-10-21 | Buy | $10.0M |
| DUGGAN ROBERT W | 2025-09-11 | Buy | $90K |
| Zanganeh Mahkam | 2025-09-11 | Buy | $90K |
| DUGGAN ROBERT W | 2025-09-10 | Buy | $5.9M |
| Zanganeh Mahkam | 2025-09-10 | Buy | $5.9M |
About SEC Form 4
SEC Form 4 is a mandatory disclosure filed when corporate insiders — officers, directors, or shareholders owning more than 10% of a company's stock — buy or sell shares. These filings must be submitted within two business days of the transaction.
Insider purchases may reflect management's confidence in the company's prospects, though this is not always the case. Insider sales may occur for many reasons unrelated to company outlook, such as diversification, tax planning, or personal financial needs. Neither purchases nor sales should be interpreted as investment recommendations.
Only open-market purchases (code P) and sales (code S) are displayed. Grants, gifts, and other non-market transactions are excluded for clarity.
Frequently Asked Questions
How many insider trades has Summit Therapeutics Inc. had?
Summit Therapeutics Inc. (SMMT) has 11 recent insider transactions on record: 11 purchases and 0 sales. Net insider buying totals $26.6M.
Who are the key insiders trading Summit Therapeutics Inc. stock?
The most active insiders trading Summit Therapeutics Inc. stock include DUGGAN ROBERT W (Co-Chief Executive Officer), Zanganeh Mahkam (Co-Chief Executive Officer), Soni Manmeet Singh (COO and CFO). These individuals are required to report their transactions via SEC Form 4 filings.
Is there a cluster buy signal for Summit Therapeutics Inc.?
Yes. 3 different insiders have purchased Summit Therapeutics Inc. (SMMT) stock within the last 30 days, which is known as a "cluster buy" — a pattern where multiple insiders independently purchase shares within a short period. The buyers include: Zanganeh Mahkam (Co-Chief Executive Officer), Soni Manmeet Singh (COO and CFO), DUGGAN ROBERT W (Co-Chief Executive Officer). This is factual data from SEC Form 4 filings and does not constitute investment advice.
What is SEC Form 4?
SEC Form 4 is a filing required by the Securities and Exchange Commission whenever a company insider (officer, director, or 10%+ shareholder) buys or sells company stock. These filings must be submitted within two business days of the transaction and are publicly available through SEC EDGAR.
Should I follow insider trading activity?
Insider trading data can provide insight into how company insiders view their own stock, but it should not be used as the sole basis for investment decisions. Insiders may buy or sell for many reasons unrelated to company performance, including portfolio diversification, tax planning, or personal financial needs. This information is provided for research purposes only and does not constitute investment advice.
Where does this data come from?
All insider trading data on this page is sourced from SEC EDGAR Form 4 filings, which are publicly available government-mandated disclosures. The data is processed and verified by Billiver. Only open-market purchases (P) and sales (S) are shown.